Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo

Journal of Virology

Volumn 80, Issue 16, 2006, Pages 7799-7806

  Ulbrandt, Nancy D ^a   Ji, Hong ^a   Patel, Nita K ^a   Riggs, Jeffrey M ^a   Brewah, Yambasu A ^a   Ready, Shannon ^a   Donacki, Nanci E ^a   Folliot, Karyn ^a   Barnes, Arnita S ^a   Senthil, Kannaki ^a   Wilson, Susan ^a   Chen, Mingzhong ^a   Clarke, Lori ^a   MacPhail, Mia ^a   Li, Jia ^a   Woods, Robert M ^a   Coelingh, Kathy ^a   Reed, Jennifer L ^a   McCarthy, Michael P ^a   Pfarr, David S ^a   Osterhaus, Albert D M E ^b   Fouchier, Ron A M ^b   Kiener, Peter A ^a   Suzich, JoAnn A ^a   more..

^a MEDIMMUNE   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN F; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BRONCHIOLITIS; CONTROLLED STUDY; COUGHING; HAMSTER; HUMAN; HUMAN CELL; HUMAN METAPNEUMOVIRUS; IN VITRO STUDY; IN VIVO STUDY; LOWER RESPIRATORY TRACT INFECTION; MOUSE; NONHUMAN; PARAMYXOVIRUS; PNEUMONIA; PNEUMOVIRINAE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT DISEASE; VIRUS NEUTRALIZATION; WINTER;

ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CELLS, CULTURED; HUMANS; METAPNEUMOVIRUS; PARAMYXOVIRIDAE INFECTIONS; RESPIRATORY TRACT INFECTIONS; VIRAL FUSION PROTEINS;

CRICETINAE; HUMAN METAPNEUMOVIRUS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; PARAMYXOVIRIDAE; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 33746798064     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00318-06     Document Type: Article

References (32)

1. Atkins, J. T., P. Karimi, B. H. Morris, G. McDavid, and S. Shim. 2000. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost. Pediatr. Infect. Dis. 19:138-143.
2. Bebbington, C. R., G. Renner, S. Thomson, D. King, D. Abrams, and G. T. Yarranton. 1992. High level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology 10:169-175.
3. Biacchesi, S., M. H. Skiadopoulos, G. Boivin, C. T. Hanson, B. R. Murphy, P. L. Collins, and U. J. Buchholz. 2003. Genetic diversity between human metapneumovirus subgroups. Virology 315:1-9.
4. Boivin, G., I. Mackay, T. P. Sloots, S. Madhi, F. Freymuth, D. Wolf, Y. Shemer-Avni, H. Ludewick, G. C. Gray, and E. LeBlanc. 2004. Global genetic diversity of human metapneumovirus fusion gene. Emerg. Infect. Dis. 10:1154-1157.
5. Chano, F., C. Rousseau, C. Lafarriere, M. Couillard, and H. Charest. 2005. Epidemiological survey of human metapneumovirus infection in a large pediatric tertiary care center. J. Clin. Microbiol. 43:552-5525.
6. Crowe, J. E. 2004. Human metapneumovirus as a major cause of human respiratory tract disease. Pediatr. Infect. Dis. J. 23:S215-S221.
7. de St Groth, F. S., and D. Scheidegger. 1980. Production of monoclonal antibodies: strategy and tactics. J. Immunol. Methods 35:1-21.
8. Falsey, A. R., D. Erdman, L. J. Anderson, and E. E. Walsh. 2003. Human metapneumovirus infections in young and elderly adults. J. Infect. Dis. 187: 785-790.
9. The IMpact-RSV Study Group. 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduced hospitalization from respiratory syncytial virus infection in high risk infants. Pediatrics 102:531-537.
10. Ison, M. G., and F. G. Hayden. 2002. Viral infections in immunocompromised patients: what's new with respiratory viruses? Curr. Opin. Infect. Dis. 15:355-367.
11. Johnson, S., C. Oliver, G. A. Prince, V. G. Hemming, D. S. Pfarr, S. C. Wang, M. Dormitzer, J. O'Grady, S. Koenig, J. K. Tamura, R. Woods, G. Bansal, D. Couchenour, E. Tsao, W. C. Hall, and J. F. Young. 1997. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176:1215-1224.
12. Johnsson, B., S. Lofas, and G. Lindquist. 1991. Immobilization of proteins to a carboxymethyldextran-modified gold surface for bispecific interaction analysis in surface plasmon resonance sensors. Anal. Biochem. 198:268-277.
13. Karber, G. 1931. 50% end-point calculation. Arch. Exp. Pathol. Pharmakol. 162:480-483.
14. Larcher, C., C. Geltner, H. Fischer, D. Nachbaur, L. C. Muller, and H. P. Huemer. 2005. Human metapneumovirus infection in lung transplant recipients: clinical presentation and epidemiology. J. Heart Lung Transplant. 24:1891-1901.
15. Leung, J., F. Esper, C. Weibel, and J. S. Kahn. 2005. Seroepidemiology of human metapneumovirus (hMPV) on the basis of a novel enzyme-linked immunosorbent assay utilizing hMPV fusion protein expressed in recombinant vesicular stomatitis virus. J. Clin. Microbiol. 43:1213-1219.
16. Ma, X., R. Endo, T. Ebihara, N. Ishiguro, H. Ishiko, and H. Kikuta. 2005. Production and characterization of neutralizing monoclonal antibodies against human metapneumovirus F protein. Hybridoma 24:201-205.
17. MacPhail, M., J. H. Schickli, R. S. Tang, J. Kaur, C. Robinson, R. A. Fouchier, A. D. Osterhaus, R. R. Spaete, and A. A. Halle. 2004. Identification of small-animal and primate models for evaluation of vaccine candidates for human metapneumovirus (hMPV) and implications for hMPV vaccine design. J. Gen. Virol. 85:1655-1663.
18. Martino, R., R. P. Porras, N. Rabella, J. V. Williams, E. Ramila, N. Margall, R. Labeaga, J. E. Crowe, Jr., P. Coll, and J. Sierra. 2005. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol. Blood Marrow Transplant. 11:781-796.
19. Mejías, A., S. Chávez-Bueno, and O. Ramillo. 2004. Human metapneumovirus: a not so new virus. Pediatr. Infect. Dis. J. 23:1-10.
20. Robinson, J. L., B. E. Lee, N. Bastein, and Y. Li. 2005. Seasonality and clinical features of human metapneumovirus infection in children in northern Alberta. J. Med. Virol. 76:98-105.
21. Sinaniotis, C. A. 2004. Viral pneumoniae in children: incidence and aetiology. Paediatr. Respir. Rev. 5:S197-S200.
22. Skiadopoulos, M. H., S. Biacchesi, U. J. Buchholz, J. M. Riggs, S. R. Surman, E. Amaro-Carambot, J. M. McAuliffe, W. R. Elkins, M. St. Claire, P. L. Collins, and B. R. Murphy. 2004. The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J. Virol. 78:6927-6937.
23. Sorrentino, M., T. Powers, et al. 2000. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. Pediatr. Infect. Dis. J. 19:1068-1071.
24. Tang, R. S., J. H. Schickli, M. MacPhail, F. Fernandes, L. Bicha, J. Spaete, R. A. Fouchier, A. D. Osterhaus, R. Spaete, and A. A. Haller. 2003. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3′ proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. J. Virol. 77:10819-10828.
25. Ulloa-Gutierrez, R., P. Skippen, A. Synnes, M. Seear, N. Bastein, Y. Li, and J. C. Forbes. 2004. Life-threatening human metapneumovirus pneumonia requiring extracorporeal membrane oxygenation in a preterm infant. Pediatrics 114:517-519.
26. van den Hoogen, B. G., J. C. de Jong, J. Groen, T. Kuiken, R. de Groot, R. A. Fouchier, and A. D. Osterhaus. 2001. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat. Med. 7:719-724.
27. van den Hoogen, B. G., T. M. Bestebroer, A. D. Osterhaus, and R. A. Fouchier. 2002. Analysis of the genomic sequence of a human metapneumovirus. Virology 295:119-132.
28. van den Hoogen, B. G., S. Herfst, L. Sprong, P. A. Cane, E. Forleo-Neto, R. L. de Swart, A. D. Osterhaus, and R. A. Fouchier. 2004. Antigenic and genetic variability of human metapneumoviruses. Emerg. Infect. Dis. 10:658-666.
29. Welliver, R. C. 2003. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J. Pediatr. 143:S112-S117.
30. Williams, J. V., P. A. Harris, S. J. Tollefson, L. L. Halburnt-Rush, J. Pingsterhaus, K. M. Edwards, P. F. Wright, and J. E. Crowe, Jr. 2004. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N. Engl. J. Med. 350:443-450.
31. Wu, H., D. S. Pfarr, Y. Tang, L. L. An, N. K. Patel, J. D. Watkins, W. D. Huse, P. A. Kiener, and J. F. Young. 2005. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J. Mol. Biol. 350:126-144.
32. Wyde, P. R., S. N. Chetty, A. M. Jewell, G. Boivin, and P. A. Piedra. 2003. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antivir. Res. 60:51-59.